Ad Com set for April 23 for review of Lilly and Incyte's baricitinib in rheumatoid arthritis

|About: Incyte Corporation (INCY)|By:, SA News Editor

The FDA's Arthritis Advisory Committee will meet on April 23 to discuss Eli Lilly's (LLY +1.2%) marketing application seeking approval for baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to or are intolerant of methotrexate.

Lilly is co-developing the oral JAK inhibitor with Incyte (INCY -0.5%).